With improved surgical technique and understanding of the disease, radical prostatectomy (RP) is increasingly offered for locally advanced prostate cancer. RP in T3 prostate cancer may be associated with incomplete local tumour control, and functional outcomes may be worse because of the need for wider resection margins. We examined the oncological and functional outcomes in of patients undergoing RP in T2 and T3 prostate cancer.
INTRODUCTION AND OBJECTIVES:
With improved surgical technique and understanding of the disease, radical prostatectomy (RP) is increasingly offered for locally advanced prostate cancer. RP in T3 prostate cancer may be associated with incomplete local tumour control, and functional outcomes may be worse because of the need for wider resection margins. We examined the oncological and functional outcomes in of patients undergoing RP in T2 and T3 prostate cancer.
METHODS: A retrospective review was conducted including all patients listed in the SA-PCCOC database who underwent RP with stage pT2a-c or pT3a-b prostate cancer (any PSA, and any biopsy Gleason score). Demographics, PSA values, imaging characteristics, pathological details, intraoperative blood loss and length of stay were recorded. Oncological outcome was assessed by final histology report, margin status, and presence of and time to biochemical recurrence. Functional outcomes were assessed using the EPIC 26 questionnaire (urinary incontinence and erectile dysfunction domains).
RESULTS: 1254 patients underwent RP for pT2, and 1297 patients for pT3 prostate cancer. In the patients with pT2 prostate cancer PSA values were <4 in 9.4%, 4-10 in 45.8%, 10-20 in 10.7% and > 20 in 1.4%. The patients with pT3 prostate cancer PSA values were <4 in 5.6%, 4-10 in 37.2%, 10-20 in 14.3% and > 20 in 3.6%. The Gleason scores in patients with pT2 were Gleason 3þ3 in 51.9%, 3þ4 in 30.3%, 4þ3 in 9.4%, 4þ4 in 5.2%, 5þ4 in 3.2% patients. The Gleason scores in patients with pT3 were Gleason 3þ3 in 25.8%, 3þ4 in 35.1%, 4þ3 in 21.7%, 4þ4 in 16.1%, 5þ4 in 1.3% patients. No significant difference was observed in blood loss and length of stay between the groups (p¼0.85 and 0.83, respectively). Nerve sparing surgery was more frequently performed in patients with pT2 disease compared with pT3 (85.7% vs 75.8%, p<0.001). Despite this, the erectile dysfunction and urinary continence rates were comparable in the two groups. pT3 patients were at higher risk of biochemical recurrence (BCR) than pT2 patients (HR 1.96, 95% CI 1.6-2.5, p<0.001). Factors influencing biochemical recurrence were PSA >20 at presentation (HR 1.9, 95% CI 1.7-5.3, p<0.001), positive margin (HR 2.9, 95% CI 2.4-3.5, p<0.001), high Gleason scores-Gleason 4þ3 (HR 4.2, 95% CI 3.0-5.9, p<0.001) and Gleason >7(HR 5.2, 95% CI 3.6-7.7, p<0.001).
CONCLUSIONS: Although T3 patients have an increased risk of BCR than T2 patients, the functional outcomes are comparable. This is despite a difference in the rate of nerve-sparing surgery in the groups. risk stratification. PSA nadir after RP is a strong predictor of biochemical recurrence (BCR). However, the time to nadir (TTN) has not been studied in the post-RP setting. We analyzed the association between PSA nadir level and TTN with BCR risk after RP among patients in the Shared Equal Access Research Cancer Hospital (SEARCH) Database.
METHODS: Using SEARCH, we identified men who either had an undetectable PSA (0 ng/ml) within 1-3 months after RP, or a detectable PSA within 1-3 months after RP and a follow-up PSA within 3-6 months after RP (n¼1882). Men with a BCR or secondary treatment within 6 months of RP were excluded. Nadir was the lowest PSA within 1-6 months. We divided patients into 4 nadir groups: undetectable nadir and TTN 3-6 months (n¼139), undetectable nadir and TTN 1-2.9 months (n¼1290), detectable nadir and TTN 3-6 months (n¼146), and detectable nadir and TTN 1-2.9 months (n¼307). A Cox model was used to test the association between nadir group and risk of BCR. Time zero for all groups was 6 months after RP. The model was adjusted for race, BMI, age, year, surgical center, pre-RP PSA, Gleason score, and pathological features.
RESULTS: During a median follow-up of 65 months (IQR 29-111), 480/1882 (26%) men had a BCR. Among men with an undetectable PSA nadir and TTN 3-6 months, median time to first PSA was 1.6 months (IQR 1.3-2.1 months) after RP and median initial PSA was 0.02 (IQR 0.01-0.03). Among men with a detectable PSA at 1-3 months, 48% had a lower follow-up PSA 3-6 months after RP which was undetectable in 23% and lower but still detectable in 25%. Men with an undetectable PSA nadir and TTN 1-2.9 months had similar risk of BCR to men with an undetectable PSA nadir and TTN 3-6 months (HR 0.90, p¼0.63). However, those with detectable nadir had increased risk of BCR (TTN 3-6 months: HR 2.01, p¼0.009; TTN 1-2.99 months: HR 3.83, p<0.001), and those with shorter TTN (1-2.99 months) had higher risk of BCR than men with longer TTN (3-6 months) (p<0.001).
CONCLUSIONS: Among men undergoing RP with an undetectable PSA nadir, there was no association between TTN and risk of BCR. However, a shorter TTN was associated with an increased risk of BCR in men with detectable nadir. Intriguingly, nearly half of the men with a detectable PSA in first 3 months after RP had a lower follow-up PSA between 3 and 6 months after RP. This is contrary to common thinking that the first PSA after surgery is the nadir.
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MRI USE ALTERS PROSTATE CANCER MANAGEMENT PATTERNS: TREATMENT TRENDS IN THE IMAGE-GUIDED BIOPSY ERA.
INTRODUCTION AND OBJECTIVES:
As the use of MRI to diagnose prostate cancer (PCa) becomes established, knowledge of its effect on treatment patterns is needed to better counsel patients. We describe the distribution of PCa treatment modalities in the MRI/TRUSfusion biopsy (FBx) era at our center to investigate the role of FBx in modulating PCa management patterns.
METHODS: A retrospective review was performed on a prospectively maintained database of all men who underwent MRI/TRUS FBx at the National Institutes of Health from 2007 to present. Patient demographics, clinical data, imaging, pathology, treatment and outcomes were recorded. Patients were stratified by treatment into active surveillance (AS), radical prostatectomy (RP), radiation therapy (RT) þ/-androgen deprivation therapy, or other therapy (including experimental treatments, focal laser ablation (FLA) or medical therapy). Groups were compared using t-test, Fischer exact test, and ANOVA Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e631
